Research programme: anti-CLEVER-1 antibodies - Faron Pharmaceuticals

Drug Profile

Research programme: anti-CLEVER-1 antibodies - Faron Pharmaceuticals

Alternative Names: Clevegen®; FP-1115; FP-1302; FP-1304

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Faron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action STAB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Inflammation

Most Recent Events

  • 25 Jul 2016 Faron signed an agreement with Abzena to manufacture Clevegen®
  • 14 Jan 2016 Discontinued for Inflammation in Finland (Parenteral)
  • 15 Oct 2015 Preclinical development is ongoing in Finland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top